213 related articles for article (PubMed ID: 7873461)
1. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Conte PF; Giannessi PG; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford JM
Ann Oncol; 1994; 5 Suppl 7():S41-4. PubMed ID: 7873461
[TBL] [Abstract][Full Text] [Related]
2. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Conte PF; Latreille J; Mauriac L; Calabresi F; Santos R; Campos D; Bonneterre J; Francini G; Ford JM
J Clin Oncol; 1996 Sep; 14(9):2552-9. PubMed ID: 8823335
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
4. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
Tyrrell CJ
Ann Oncol; 1994; 5 Suppl 7():S37-40. PubMed ID: 7532992
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Theriault RL; Lipton A; Hortobagyi GN; Leff R; Glück S; Stewart JF; Costello S; Kennedy I; Simeone J; Seaman JJ; Knight RD; Mellars K; Heffernan M; Reitsma DJ
J Clin Oncol; 1999 Mar; 17(3):846-54. PubMed ID: 10071275
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.
Hultborn R; Gundersen S; Ryden S; Holmberg E; Carstensen J; Wallgren UB; Killany S; Andreassen L; Carlsson G; Fahl N; Hatschek T; Sommer HH; Hessman Y; Hornmark-Stenstam B; Johnsborg S; Klepp R; Laino R; Niklasson LG; Rudenstam CM; Sundbeck A; Söderberg M; Tejler G
Anticancer Res; 1999; 19(4C):3383-92. PubMed ID: 10629624
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
[TBL] [Abstract][Full Text] [Related]
9. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Lipton A; Porter L; Blayney D; Sinoff C; Wheeler H; Simeone JF; Seaman JJ; Knight RD; Heffernan M; Mellars K; Reitsma DJ
J Clin Oncol; 1998 Jun; 16(6):2038-44. PubMed ID: 9626201
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
Lipton A; Glover D; Harvey H; Grabelsky S; Zelenakas K; Macerata R; Seaman J
Ann Oncol; 1994; 5 Suppl 7():S31-5. PubMed ID: 7532991
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
18. The role of disodium pamidronate in the management of bone pain due to malignancy.
Groff L; Zecca E; De Conno F; Brunelli C; Boffi R; Panzeri C; Cazzaniga M; Ripamonti C
Palliat Med; 2001 Jul; 15(4):297-307. PubMed ID: 12054147
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
